Dohad, Suhail

Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial

Azizi, M., Schmieder, R. E., Mahfoud, F., Weber, M. A., Daemen, J., Davies, J., Basile, J., Kirtane, A. J., Wang, Y., Lobo, M. D., et al. (2018) · The Lancet

Blood Pressure and Hypertension StudiesRenal and Vascular Pathologies

Cited by 740

Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial

Azizi, M., Sanghvi, K., Saxena, M., Gosse, P., Reilly, J. P., Levy, T., Rump, L. C., Persu, A., Basile, J., Bloch, M. J., et al. (2021) · The Lancet

Blood Pressure and Hypertension StudiesRenal and Vascular Pathologies

Cited by 439

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Endovascular Ultrasound Renal Denervation to Treat Hypertension: The RADIANCE II Randomized Clinical Trial

Azizi, M., Saxena, M., Wang, Y., Jenkins, J. S., Devireddy, C., Rader, F., Fisher, N. D. L., Schmieder, R. E., Mahfoud, F., Lindsey, J., et al. (2023) · JAMA

Blood Pressure and Hypertension StudiesRenal and Vascular Pathologies

Cited by 199

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118